CSPG4 and ovarian cancer: In a recent preclinical study, the hypomethylating drug decitabine (Figure 1) could be exploited to upregulate the well-established melanoma antigen chondroitin sulfate proteoglycan 4 (CSPG4) in originally CSPG4-negative ovarian cancer cells [73].